Pulmonx (LUNG) Current Deferred Revenue (2019 - 2025)

Pulmonx (LUNG) has reported Current Deferred Revenue for 7 consecutive years, with $100000.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Current Deferred Revenue fell 25.93% year-over-year to $100000.0 in Q4 2025; TTM through Dec 2025 was $100000.0, a 25.93% decrease from a year earlier, with the FY2025 full-year figure at $100000.0, down 25.93% from the prior year.
• Current Deferred Revenue was $100000.0 for Q4 2025 at Pulmonx, roughly flat from $100000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $200000.0 in Q3 2021 and troughed at $100000.0 in Q1 2021.
• A 5-year average of $119450.0 and a median of $107000.0 in 2023 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue soared 100.0% in 2021 and tumbled 47.0% in 2022, its largest moves.
• Over 5 years, Current Deferred Revenue stood at $200000.0 in 2021, then sank by 40.0% to $120000.0 in 2022, then slipped by 13.33% to $104000.0 in 2023, then gained by 29.81% to $135000.0 in 2024, then slipped by 25.93% to $100000.0 in 2025.
• The last three Current Deferred Revenue figures came in at $100000.0 (Q4 2025), $100000.0 (Q3 2025), and $100000.0 (Q2 2025), per Business Quant data.